A software platform for real-time and automated simultaneous analysis and detection of genetic diseases
Eight out of ten rare diseases have a genetic cause. Often, they are chronic and life-threatening, and it takes seven years on average to receive an accurate diagnosis. Because of that, we developed Phivea®, a software platform for real-time and automated simultaneous analysis and detection of genetic diseases using Oxford Nanopore Technologies (ONT). It enables extensive numerical and visualization analysis and accurate, systematic and timely diagnosis significantly improving disease management.
The Phivea® platform analyzes the .fastq files generated by GridION x5 (ONT) and accesses them using a shared file system. The analysis process includes four phases:
1. Quality check (read length 900-1200bp with average Phred quality score above 8)
2. Demultiplexing (this is done using Tochlex, a method for real-time demultiplexing ONT reads)
3. Chromosome classification (BLAST algorithm is used to compare the sequence with a library and
find the sequence characteristic specific for a particular chromosome)
4. Genetic disease classification and analysis report generation (Phivea® performs discriminant
analysis of the patients’ samples compared to controls and calculates the probability of presence
of genetic disorder)
The Phivea® platform can be applied directly on the stream of base-called DNA reads generated by the ONT device. It exceeds the limits of the real-time monitoring and analysis per DNA sample, which can significantly reduce the overall costs. The calculated throughput of the analysis pipeline is 4120 reads/s measured on a referent hardware architecture using thread parallelism of 10. Also, the current version of the Phivea® platform managed to correctly identify 6 different genetic disorders (Klinefelter, Turner, Down, Edwards, Patau and Prader-Willi/Angelman syndromes) with sensitivity and specificity higher than 90% on a patient level. Our technology was tested and validated on a mix of real and synthetically prepared samples, but the obtained results can be directly extrapolated for analysis and detection of other genetic disorders.
Download the abstract here.
15 Nov 2022gMendel® announced today its first Board of Directors and appointments of Lars Staal Wegner, Chairman, and Hanna Pyokari, Member, effective November 1st, 2022.
27 Sep 2022gMendel® moves into an investment agreement with Polish biotech company genXone for further cooperation in diagnosis of genetic disorders.
29 Aug 2022gMendel® will join TechBBQ on 14 and 15 September to showcase its breakthrough technology for the diagnosis of genetic disorders.
11 May 2022Denmark's vision to become a front-runner in the use of artificial intelligence reflects on the country's national strategy for AI.